Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017

A 22% decline in hepatitis C sales year-over-year was offset somewhat by a 17% uptick for the HIV franchise, but the virology powerhouse is guiding for continued HCV falloff in 2017.